Karin Schelch

1.4k total citations · 1 hit paper
39 papers, 737 citations indexed

About

Karin Schelch is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Karin Schelch has authored 39 papers receiving a total of 737 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 15 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Karin Schelch's work include Occupational and environmental lung diseases (20 papers), Lung Cancer Research Studies (9 papers) and Fibroblast Growth Factor Research (7 papers). Karin Schelch is often cited by papers focused on Occupational and environmental lung diseases (20 papers), Lung Cancer Research Studies (9 papers) and Fibroblast Growth Factor Research (7 papers). Karin Schelch collaborates with scholars based in Austria, Hungary and Australia. Karin Schelch's co-authors include Michael Grusch, Walter Berger, Eva Reichhart, Álvaro Inglés‐Prieto, Harald Janovjak, Balázs Döme, Zsolt Megyesfalvi, Glen Reid, Kristiina Boettiger and Konrad Höetzenecker and has published in prestigious journals such as The EMBO Journal, PLoS ONE and Cancer Research.

In The Last Decade

Karin Schelch

34 papers receiving 732 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

2023 179 citations Zsolt Megyesfalvi, Simon Heeke et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karin Schelch Austria	14	372	226	163	141	108	39	737
Weihao Liu China	14	249 0.7×	133 0.6×	89 0.5×	49 0.3×	226 2.1×	45	760
Claire B. Pollock United States	8	484 1.3×	308 1.4×	127 0.8×	29 0.2×	31 0.3×	10	815
Jessica Charlet United States	10	543 1.5×	86 0.4×	44 0.3×	104 0.7×	27 0.3×	14	742
Daniele Simoneschi United States	8	514 1.4×	145 0.6×	54 0.3×	36 0.3×	13 0.1×	11	730
Anjan K. Pradhan United States	20	425 1.1×	239 1.1×	63 0.4×	77 0.5×	13 0.1×	33	854
Mayumi Fujita Japan	17	406 1.1×	166 0.7×	96 0.6×	22 0.2×	36 0.3×	29	711
Deema Hussein Saudi Arabia	15	858 2.3×	255 1.1×	74 0.5×	13 0.1×	140 1.3×	37	1.2k
Kathryn E. Aziz United States	10	477 1.3×	123 0.5×	111 0.7×	12 0.1×	28 0.3×	17	895
Sinoula Apostolou Australia	17	376 1.0×	71 0.3×	83 0.5×	27 0.2×	32 0.3×	23	672
Elle Koren Israel	11	445 1.2×	147 0.7×	154 0.9×	18 0.1×	13 0.1×	13	709

Countries citing papers authored by Karin Schelch

Since Specialization

Citations

This map shows the geographic impact of Karin Schelch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Schelch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Schelch more than expected).

Fields of papers citing papers by Karin Schelch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Schelch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Schelch. The network helps show where Karin Schelch may publish in the future.

Co-authorship network of co-authors of Karin Schelch

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Schelch. A scholar is included among the top collaborators of Karin Schelch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Schelch. Karin Schelch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schelch, Karin, Dominik Kirchhofer, Gerald Timelthaler, et al.. (2025). Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma. British Journal of Cancer. 133(9). 1391–1400.

Boettiger, Kristiina, Zsolt Megyesfalvi, Dominik Kirchhofer, et al.. (2025). Unveiling the powerhouse: ASCL1-driven small cell lung cancer is characterized by higher numbers of mitochondria and enhanced oxidative phosphorylation. Cancer & Metabolism. 13(1). 16–16.

Lang, Christian, Zsolt Megyesfalvi, Felicitas Oberndorfer, et al.. (2024). C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer. World Journal of Surgical Oncology. 22(1). 57–57. 2 indexed citations

Boettiger, Kristiina, Zsolt Megyesfalvi, Simon Heeke, et al.. (2024). Small cells – big issues: biological implications and preclinical advancements in small cell lung cancer. Molecular Cancer. 23(1). 41–41. 19 indexed citations

Slany, Astrid, Christine Pirker, Johanna C. Mader, et al.. (2023). Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin. Journal of Experimental & Clinical Cancer Research. 42(1). 27–27. 13 indexed citations

Slany, Astrid, Christine Pirker, Johanna C. Mader, et al.. (2023). Primary and hTERT-Transduced Mesothelioma-Associated Fibroblasts but Not Primary or hTERT-Transduced Mesothelial Cells Stimulate Growth of Human Mesothelioma Cells. Cells. 12(15). 2006–2006. 2 indexed citations

Boettiger, Kristiina, Ildikó Kovács, Christian Lang, et al.. (2023). Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair. Clinical Cancer Research. 29(22). 4644–4659. 15 indexed citations

Megyesfalvi, Zsolt, János Fillinger, Orsolya Pipek, et al.. (2023). Comparative expression analysis of immune-related markers in surgically resected lung neuroendocrine neoplasms. Lung Cancer. 181. 107263–107263. 4 indexed citations

Schelch, Karin, Thomas Mohr, Thomas Klikovits, et al.. (2023). Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis. Thoracic Cancer. 14(22). 2177–2186. 1 indexed citations

10.

Schelch, Karin, Thomas G. Johnson, Verena Kopatz, et al.. (2023). Targeting YB-1 via entinostat enhances cisplatin sensitivity of pleural mesothelioma in vitro and in vivo. Cancer Letters. 574. 216395–216395. 12 indexed citations

11.

Schenkeveld, Walter D. C., Maura Tomatis, Karin Schelch, et al.. (2022). The Potential Contribution of Hexavalent Chromium to the Carcinogenicity of Chrysotile Asbestos. Chemical Research in Toxicology. 35(12). 2335–2347. 4 indexed citations

12.

Schelch, Karin, Thomas Mohr, Rupert L. Mayer, et al.. (2021). EGF Induces Migration Independent of EMT or Invasion in A549 Lung Adenocarcinoma Cells. Frontiers in Cell and Developmental Biology. 9. 634371–634371. 23 indexed citations

13.

Johnson, Thomas G., Karin Schelch, Sunali Mehta, Andrew Burgess, & Glen Reid. (2019). Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma. Frontiers in Cell and Developmental Biology. 7. 221–221. 25 indexed citations

14.

Schelch, Karin, Michaela B. Kirschner, Marissa Williams, et al.. (2017). OA02.01 The microRNA-15/16 Family Regulates Tumor Cell Growth via Fibroblast Growth Factor Signals in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 12(1). S246–S246. 2 indexed citations

15.

Hoda, Mir Alireza, Christine Pirker, Karin Schelch, et al.. (2016). Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro. Molecular Cancer Therapeutics. 15(10). 2357–2369. 17 indexed citations

16.

Garay, Tamás, Eszter Molnár, Éva Juhász, et al.. (2015). Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations. Pathology & Oncology Research. 21(4). 957–968. 9 indexed citations

17.

Nguyen, Chi Huu, Martin Zehl, Atanas G. Atanasov, et al.. (2015). A eudesmane-type sesquiterpene isolated from Pluchea odorata (L.) Cass. combats three hallmarks of cancer cells: Unrestricted proliferation, escape from apoptosis and early metastatic outgrowth in vitro. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 777. 79–90. 5 indexed citations

18.

Grusch, Michael, Karin Schelch, Eva Reichhart, et al.. (2014). Spatio‐temporally precise activation of engineered receptor tyrosine kinases by light. The EMBO Journal. 33(15). 1713–1726. 199 indexed citations

19.

Inglés‐Prieto, Álvaro, Eva Reichhart, Karin Schelch, Harald Janovjak, & Michael Grusch. (2014). The optogenetic promise for oncology: Episode I. Molecular & Cellular Oncology. 1(4). e964045–e964045. 5 indexed citations

20.

Wright, Casey M., Michaela B. Kirschner, Yuen Yee Cheng, et al.. (2013). Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM). PLoS ONE. 8(8). e70940–e70940. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact